TABLE 3.
Rates of patients switching or discontinuing mepolizumab treatment in pre-pandemic period
| All | Belgium | Spain | France | Croatia | Italy | Lithuania | The Netherlands | Portugal | Slovenia | Turkey | |
| Patients | 671 | 109 | 53 | 69 | 19 | 104 | 21 | 247 | 15 | 33 | 1 |
| Patients who continued using mepolizumab at follow-up | 475 (71) | 92 (84) | 40 (76) | 27 (39) | 15 (79) | 96 (92) | 19 (90) | 141 (57) | 15 (100) | 30 (91) | |
| Patients who stopped all biological therapy during follow-up | 94 (14) | 14 (13) | 8 (15) | 23 (33) | 4 (21) | 6 (6) | 1 (5) | 35 (14) | 0 (0) | 3 (9) | |
| Patients who switched to another biologic during follow-up | 101 (15) | 3 (3) | 5 (1) | 19 (28) | 0 (0) | 2 (2) | 1 (5) | 71 (29) | 0 (0) | 0 (0) | |
| Omalizumab | 6 | 0 | 0 | 2 | 1 | 0 | 3 | ||||
| Reslizumab | 37 | 0 | 2 | 0 | 0 | 0 | 35 | ||||
| Benralizumab | 52 | 3 | 3 | 16 | 1 | 1 | 28 | ||||
| Dupilumab | 6 | 0 | 0 | 1 | 0 | 0 | 5 | ||||
| Months of mepolizumab therapy in patients who stopped or switched during follow-up | # | 6 (5.2–9.6) |
4.9 (3.4–9.2) |
6 (5–9.9) |
4.8 (3.9–5) |
7.2 (3.2–8.2) |
5.6 (4.2–7) |
5.5 (3.6–8.4) |
11.1 (7.4–11.5) |
Data are presented as n, n (%) or median (interquartile range). #: not calculable from medians extracted.